Search Results - "Agoropoulou, C"

Gene structure and expression of the Corynebacterium flavum N13 ask-asd operon by FOLLETTIE, M. T, PEOPLES, O. P, AGOROPOULOU, C, SINSKEY, A. J

“…Article Usage Stats Services JB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis by Kappos, Ludwig, Radue, Ernst-Wilhelm, O'Connor, Paul, Polman, Chris, Hohlfeld, Reinhard, Calabresi, Peter, Selmaj, Krzysztof, Agoropoulou, Catherine, Leyk, Malgorzata, Zhang-Auberson, Lixin, Burtin, Pascale

“…In this 24-month, randomized trial involving patients with relapsing–remitting multiple sclerosis, oral fingolimod reduced the rates of relapse and disability…”
Get full text

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study by Devonshire, Virginia, MD, Havrdova, Eva, MD, Radue, Ernst Wilhelm, Prof, O'Connor, Paul, MD, Zhang-Auberson, Lixin, MD, Agoropoulou, Catherine, PhD, Häring, Dieter Adrian, PhD, Francis, Gordon, MD, Kappos, Ludwig, Prof

“…Summary Background Fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720…”
Get full text

CD59 expression and complement susceptibility of human neuronal cell line (NTera2) by Agoropoulou, C, Wing, M G, Wood, A

“…The present study analysed the susceptibility of neuronal cells to human complement. A human neuronal precursor cell line (NTera2) which can be induced to…”
Get more information

Neuronal protection of oligodendrocytes from antibody-independent complement lysis by Agoropoulou, C, Piddlesden, S J, Lachmann, P J, Wing, M G

“…CULTURED rat oligodendrocytes are lysed by complement via antibody—independent activation of the classical pathway. This susceptibility to complement lysis has…”
Get full text

Fingolimod (FTY720) oral for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 FORCIDP trial by Hughes, R., Dalakas, M., Latov, N., Léger, J.-M., Merkies, I., Nobile-Orazio, E., Agoropoulou, C., Häring, D.A., Zhang-Auberson, L., von Rosenstiel, P., Hartung, H.-P.

Get full text

Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004) by Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Jin, J., Zhang-Auberson, L., Francis, G.

“…Abstract only…”
Get full text

F ingolimod (FTY720) or al for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy ( CIDP ): Study design of the phase 3 FORCIDP trial by Hughes, R, Dalakas, M, Latov, N, Léger, J.-M, Merkies, I, Nobile-Orazio, E, Agoropoulou, C, Häring, D.A, Zhang-Auberson, L, von Rosenstiel, P, Hartung, H.-P

Get full text

Oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis: baseline patient demographics and disease characteristics from a 2-year phase III trial (FREEDOMS) by Kappos, L, Polman, CH, Radue, E-W, O'Connor, P, Calabresi, P A, Hohlfeld, R, Agoropoulou, C, Pohlmann, H, de Vera, A

“…Background: A 6-month, phase II, placebo-controlled trial in 281 patients with relapsing multiple sclerosis (MS) demonstrated that the sphingosine-1-phosphate…”
Get full text

Extended-Release Dexmethylphenidate: Efficacy and Safety in Children with Attention-Deficit/Hyperactivity Disorder by Lopez, F., Muniz, R., Pestreich, L., Liu, F., Jiang, H., Agoropoulou, C.

Get full text